news

CUPERTINO, Calif., Nov. 12 /PRNewswire-FirstCall/ — DURECT Corporation (Nasdaq: DRRX) announced today financial results for the three months ended September 30, 2002. (Photo: http://www.newscom.com/cgi-bin/prnh/20020717/DRRXLOGO ) DURECT’s net loss for the three months ended September 30, 2002 was $9.1 million or 19 cents per share, compared to $8.9 million or 19 cents per share for the […]

CUPERTINO, Calif., Nov. 12 /PRNewswire-FirstCall/ — DURECT Corporation (Nasdaq: DRRX) announced today that it has amended its development and commercialization agreement with ALZA Corporation under which DURECT holds exclusive rights to develop, commercialize and manufacture products using ALZA’s patented DUROS(R) technology in selected fields of use. Under the amended agreement, DURECT’s maintenance of exclusivity in

CUPERTINO, Calif., Nov. 11 /PRNewswire-FirstCall/ — DURECT Corporation (Nasdaq: DRRX) announced today that it will postpone its third quarter financial results press release and conference call to Tuesday, November 12th, 2002. The earnings release is postponed due to the announcement today by DURECT Corporation and Endo Pharmaceuticals relating to the agreement to collaborate on the

CHADDS FORD, Pa. and CUPERTINO, Calif., Nov. 11 /PRNewswire-FirstCall/ — Endo Pharmaceuticals Holdings Inc. (Nasdaq: ENDP) and DURECT Corporation (Nasdaq: DRRX), announced today that they have signed an agreement to collaborate on the development and commercialization of DURECT’s CHRONOGESIC(TM) (sufentanil) Pain Therapy System for the U.S. and Canada. The companies believe CHRONOGESIC has significant potential

CUPERTINO, Calif., Oct 30, 2002 /PRNewswire-FirstCall via COMTEX/ — DURECT Corporation (Nasdaq: DRRX) announced today that it will present at the CIBC World Markets 13th Annual Health Care Conference. The conference is being held at The Plaza Hotel in New York City. Dr. James E. Brown, Chief Executive Officer, will be presenting at the conference

CUPERTINO, Calif., Oct 16, 2002 /PRNewswire-FirstCall via COMTEX/ — In conjunction with DURECT Corporation’s (Nasdaq: DRRX) third quarter financial results press release, you are invited to listen to its conference call that will be broadcast live over the Internet on Monday, November 11th, 2002 at 4:30 p.m. EDT with Jim Brown, President and Chief Executive

CUPERTINO, Calif., Oct 4, 2002 /PRNewswire-FirstCall via COMTEX/ — DURECT Corporation (Nasdaq: DRRX) announced today that it will present at the UBS Warburg Global Life Sciences Conference. The conference is being held at The Plaza Hotel in New York City. Thomas A. Schreck, Chief Financial Officer, will be presenting at the conference on Monday, October

CUPERTINO, Calif., Aug 26, 2002 /PRNewswire-FirstCall via COMTEX/ — DURECT Corporation (Nasdaq: DRRX) announced today that, following discussions between DURECT and the FDA on DURECT’s on-going Phase III clinical trial for the CHRONOGESIC(TM) (sufentanil) Pain Therapy System, the FDA has requested that the clinical trial protocol be amended to provide for additional patient monitoring before

CUPERTINO, Calif., Aug 5, 2002 /PRNewswire-FirstCall via COMTEX/ — DURECT Corporation (Nasdaq: DRRX) announced today that it will present at the Adams, Harkness & Hill – 22nd Annual Summer Seminar. The conference is being held at The Boston Marriott Long Wharf Hotel. Dr. James E. Brown, President and Chief Executive Officer will be presenting at

CUPERTINO, Calif., Jul 29, 2002 /PRNewswire-FirstCall via COMTEX/ — DURECT Corporation (Nasdaq: DRRX) announced today financial results for the three months ended June 30, 2002. (Photo: http://www.newscom.com/cgi-bin/prnh/20020717/DRRXLOGO ) DURECT’s net loss for the three months ended June 30, 2002 was $9.9 million or 21 cents per share, compared to $21.0 million or 45 cents per